Abstract

AbCellera Biologics will report quarterly results on November 09, 2026 Post-Mkt; this preview compiles market forecasts, reviews last quarter’s trends, and highlights the key issues investors are watching this season.

Market Forecast

Consensus points to a modest rebound in revenue and a continued operating loss. For the current quarter, revenue is forecast at 6.26 million US dollars with estimated year-over-year growth of 5.90%, EBIT at a loss of 61.39 million US dollars with estimated year-over-year growth of 9.85%, and EPS at -0.17 with estimated year-over-year growth of 8.19%; gross margin, net margin, and adjusted EPS guidance are not disclosed.

The main business mix is expected to remain skewed toward R&D-related collaboration income and licensing, with lumpiness driven by program milestones and partner activity. The most promising contributor remains the licensing stream, though still small at 0.15 million US dollars last quarter, with growth highly sensitive to milestone timing and partner progress rather than steady run-rate expansion.

Last Quarter Review

Last quarter, AbCellera Biologics generated revenue of 4.05 million US dollars, posted a GAAP net loss attributable to shareholders of 55.43 million US dollars with a quarter-on-quarter growth rate of -28.41%, while gross margin, net margin, and adjusted EPS were not disclosed by the dataset; reported EPS was -0.18 with a year-over-year change of -50.00%.

A notable development was substantial underperformance versus revenue expectations, reflecting the inherent variability of milestone-driven inflows. Main business contributions were concentrated in research-related revenues of 3.90 million US dollars and licensing at 0.15 million US dollars, while year-over-year segment growth indicators were not provided; total revenue declined 76.29% year over year.

Current Quarter Outlook

Core collaboration and discovery services

The collaboration engine remains the core, with results tied to the pace of discovery programs and the progression of partnered candidates. This quarter’s stock performance will likely hinge on whether reported revenue lands near the 6.26 million US dollars forecast and whether management comments indicate steadier program initiation and milestone cadence heading into the next fiscal period. Any color suggesting faster partner advancement through preclinical stages could support the argument for improving revenue visibility, even if quarter-to-quarter figures remain choppy. Conversely, another light quarter versus the forecast could reinforce concerns that milestone timing continues to delay the transition to a more predictable revenue base.

Licensing and milestone economics

Licensing income and downstream economics are the potential source of positive operational leverage, but they remain contingent on partner progress and clinical de-risking. Investors will focus on whether milestone receipts improve sequentially from the 0.15 million US dollars level recorded last quarter and if the company indicates any near-term catalysts from partnered assets approaching IND submission or early clinical readouts. Commentary that frames a pipeline of partner programs nearing milestones could recalibrate expectations for revenue normalization and margin recovery, even while EBIT remains in a loss. If milestone flow stays muted, the path to lowering the run-rate EBIT loss of roughly 61.39 million US dollars this quarter becomes harder to underwrite.

Key stock drivers this quarter

The biggest swing factor is revenue timing against the 6.26 million US dollars estimate and the quality of backlog or signed collaborations that can translate into revenue in the next two to three quarters. The shape of operating expenses versus the forecast loss will also matter, particularly any signals on cost discipline that could narrow EBIT losses independent of milestone lumpiness. Finally, management’s narrative around the visibility of partner pipelines — including the distribution of programs by stage and any notable near-term catalysts — can influence sentiment on whether EPS trends from -0.18 last quarter to approximately -0.17 this quarter indicate an inflection or simply statistical noise.

Analyst Opinions

Most recent commentary leans cautious, emphasizing the lack of near-term revenue visibility and the continued operating losses despite a large discovery footprint. The prevailing view is that while the forecast implies a sequential revenue uptick versus last quarter’s 4.05 million US dollars, the model remains exposed to milestone timing and partner execution, which restrains confidence in near-term margin improvement. Cautious stances point to monitoring the consistency of collaboration starts and signs of milestone conversion before revisiting more constructive estimates. Investors appear to be seeking confirmation that the revenue line can stabilize above the single-digit million range with clearer line-of-sight to downstream payments; absent this, the consensus remains guarded heading into November 09, 2026.